These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34152796)

  • 1. Letter by Sarayani et al Regarding Article, "Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque".
    Sarayani A; Jugl S; Winterstein AG
    Circulation; 2021 Jun; 143(25):e1031-e1032. PubMed ID: 34152796
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Sarayani et al Regarding Article, "Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque".
    Drobni ZD; Mayrhofer T; Hoffmann U; Neilan TG
    Circulation; 2021 Jun; 143(25):e1033-e1034. PubMed ID: 34152798
    [No Abstract]   [Full Text] [Related]  

  • 3. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque.
    Drobni ZD; Alvi RM; Taron J; Zafar A; Murphy SP; Rambarat PK; Mosarla RC; Lee C; Zlotoff DA; Raghu VK; Hartmann SE; Gilman HK; Gong J; Zubiri L; Sullivan RJ; Reynolds KL; Mayrhofer T; Zhang L; Hoffmann U; Neilan TG
    Circulation; 2020 Dec; 142(24):2299-2311. PubMed ID: 33003973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to the letter to the editor 'Reply to Solinas et al, venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review' by Frere et al.
    Petrelli F; Solinas C
    Thromb Res; 2021 Dec; 208():217-218. PubMed ID: 33810866
    [No Abstract]   [Full Text] [Related]  

  • 5. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity.
    Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N
    Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between changes in coronary atherosclerotic plaque burden measured by intravascular ultrasound and cardiovascular disease outcomes: a systematic literature review.
    Forbes C; Quek RG; Deshpande S; Worthy G; Ross J; Kleijnen J; Gandra SR; Kassahun H; Wong ND; Nicholls SJ
    Curr Med Res Opin; 2016 Jun; 32(6):1143-50. PubMed ID: 26949994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Diabetes and Time on the Atherosclerotic Plaque and Cardiovascular Outcome in Patients Undergoing Iliofemoral Endarterectomy.
    van Koeverden ID; Scholtes VPW; den Ruijter HM; Hazenberg SCE; de Kleijn DPV; de Borst GJ
    Eur J Vasc Endovasc Surg; 2019 Jun; 57(6):832-841. PubMed ID: 30910497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events.
    Frerix M; Stegbauer J; Kreuter A; Weiner SM
    Arthritis Res Ther; 2014 Feb; 16(1):R54. PubMed ID: 24548804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plaque regression measured by intravascular ultrasound and reduction of cardiovascular events: not yet the case, commentary on the study of D'Ascenzo et al.
    Rocha VZ; Santos RD
    Atherosclerosis; 2013 Jan; 226(1):45-6. PubMed ID: 23177974
    [No Abstract]   [Full Text] [Related]  

  • 10. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors.
    Suarez-Almazor ME; Pundole X; Abdel-Wahab N; Johnson DB; Gupta D; Glezerman I; Cooksley T; Anderson R; Blidner A; Choi J; Dougan M; Ginex P; Girotra M; Shannon VR; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6159-6173. PubMed ID: 32856212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis.
    Zhang L; Zlotoff DA; Awadalla M; Mahmood SS; Nohria A; Hassan MZO; Thuny F; Zubiri L; Chen CL; Sullivan RJ; Alvi RM; Rokicki A; Murphy SP; Jones-O'Connor M; Heinzerling LM; Barac A; Forrestal BJ; Yang EH; Gupta D; Kirchberger MC; Shah SP; Rizvi MA; Sahni G; Mandawat A; Mahmoudi M; Ganatra S; Ederhy S; Zatarain-Nicolas E; Groarke JD; Tocchetti CG; Lyon AR; Thavendiranathan P; Cohen JV; Reynolds KL; Fradley MG; Neilan TG
    Circulation; 2020 Jun; 141(24):2031-2034. PubMed ID: 32539614
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter by Chen et al regarding article, "Role of extracellular RNA in atherosclerotic plaque formation in mice".
    Chen C; Li T; Liu J
    Circulation; 2014 Oct; 130(16):e143. PubMed ID: 25311623
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical applicability of the framingham 30-year risk score. Usefulness in cardiovascular risk stratification and the diagnosis of carotid atherosclerotic plaque].
    Masson W; Siniawski D; Krauss J; Cagide A
    Rev Esp Cardiol; 2011 Apr; 64(4):305-11. PubMed ID: 21377779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter by Cochain et al Regarding Article, "Transcriptome Analysis Reveals Nonfoamy Rather Than Foamy Plaque Macrophages Are Proinflammatory in Atherosclerotic Murine Models".
    Cochain C; Saliba AE; Zernecke A
    Circ Res; 2018 Nov; 123(11):e48-e49. PubMed ID: 30571470
    [No Abstract]   [Full Text] [Related]  

  • 15. Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease.
    Lutgens E; Seijkens TTP
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32034065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis.
    Newman JL; Stone JR
    Cardiovasc Pathol; 2019; 43():107148. PubMed ID: 31518915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Femoral plaque echogenicity and cardiovascular risk in claudicants.
    Schiano V; Sirico G; Giugliano G; Laurenzano E; Brevetti L; Perrino C; Brevetti G; Esposito G
    JACC Cardiovasc Imaging; 2012 Apr; 5(4):348-57. PubMed ID: 22498323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atherosclerotic plaque metabolism in high cardiovascular risk subjects - A subclinical atherosclerosis imaging study with
    Oliveira-Santos M; Castelo-Branco M; Silva R; Gomes A; Chichorro N; Abrunhosa A; Donato P; Pedroso de Lima J; Pego M; Gonçalves L; Ferreira MJ
    Atherosclerosis; 2017 May; 260():41-46. PubMed ID: 28349887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response by Glisic et al to Letter Regarding Article, "Associations of Endogenous Estradiol and Testosterone Levels With Plaque Composition and Risk of Stroke in Subjects With Carotid Atherosclerosis".
    Glisic M; Franco OH; Muka T
    Circ Res; 2018 Apr; 122(8):e69-e70. PubMed ID: 29650634
    [No Abstract]   [Full Text] [Related]  

  • 20. Association Between the Presence of Carotid Artery Plaque and Cardiovascular Events in Patients With Genetic Hypercholesterolemia.
    Bea AM; Civeira F; Jarauta E; Lamiquiz-Moneo I; Pérez-Calahorra S; Marco-Benedí V; Cenarro A; Mateo-Gallego R
    Rev Esp Cardiol (Engl Ed); 2017 Jul; 70(7):551-558. PubMed ID: 28215923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.